News Focus
News Focus
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 2334

Tuesday, 02/07/2023 4:10:09 PM

Tuesday, February 07, 2023 4:10:09 PM

Post# of 6017
ENTA FY1Q23* financials—12/31/22_pro_forma_cash=$270.1M† — a decrease of $37.1M relative to 9/30/22:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-34

FY1Q23 royalty revenue was $22.6M, up from $20.3M in FY4Q22.

FY1Q23 R&D expenses were $40.9M, below the run rate for ENTA’s FY2023 guidance of $210-230M. FY1Q23 SG&A expenses were $12.7M, zzz inline with ENTA’s FY2023 guidance of $46-52M.

†Including a $28.7M tax refund due from IRS.

*ENTA’s fiscal years end on September 30.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News